Literature DB >> 1797297

Local intracoronary infusions of bradykinin profoundly reduce the severity of ischaemia-induced arrhythmias in anaesthetized dogs.

A Vegh1, L Szekeres, J R Parratt.   

Abstract

Bradykinin in a dose (25 ng kg-1 min-1) which did not alter coronary flow, or saline, were infused into a small branch of the left anterior descending coronary artery in dogs anaesthetized with chloralose and urethane, for 10 min prior to coronary artery occlusion and throughout the 25 min occlusion period. The degree of inhomogeneity of conduction and epicardial ST-segment changes were measured in the ischaemic zone with a composite electrode. In control dogs, coronary artery occlusion led to severe arrhythmias with an incidence of ventricular fibrillation of 47% and tachycardia of 80% and with a mean of 528 +/- 140 ventricular premature beats. In marked contrast, those dogs administered bradykinin had no ventricular fibrillation or tachycardia and the number of premature beats was significantly less (53 +/- 19). ST-segment changes were also much less in these dogs. These results raise the possibility that bradykinin might contribute to the protective effects of preconditioning and acts as an 'endogenous myocardial protective substance'.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1797297      PMCID: PMC1908535          DOI: 10.1111/j.1476-5381.1991.tb12424.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  8 in total

1.  Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist.

Authors:  P A Martorana; B Kettenbach; G Breipohl; W Linz; B A Schölkens
Journal:  Eur J Pharmacol       Date:  1990-07-03       Impact factor: 4.432

2.  A comparison of the effects of locally and systemically administered kinins on coronary blood flow and myocardial metabolism.

Authors:  W Lochner; J R Parratt
Journal:  Br J Pharmacol Chemother       Date:  1966-01

3.  In vivo effect of bradykinin during ischemia and reperfusion: improved electrical stability two weeks after myocardial infarction in the pig.

Authors:  T J Tobé; C D de Langen; R A Tio; K J Bel; P H Mook; H Wesseling
Journal:  J Cardiovasc Pharmacol       Date:  1991-04       Impact factor: 3.105

4.  Protective effects of preconditioning of the ischaemic myocardium involve cyclo-oxygenase products.

Authors:  A Vegh; L Szekeres; J R Parratt
Journal:  Cardiovasc Res       Date:  1990-12       Impact factor: 10.787

5.  Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.

Authors:  C E Murry; R B Jennings; K A Reimer
Journal:  Circulation       Date:  1986-11       Impact factor: 29.690

6.  Effect of the blood supply to the normal noninfarcted myocardium on the incidence and severity of early post-occlusion arrhythmias in dogs.

Authors:  A Végh; L Szekeres; E Udvary
Journal:  Basic Res Cardiol       Date:  1987 Mar-Apr       Impact factor: 17.165

7.  Enzymes in normally perfused and ischaemic dog hearts which release a substance with kinin like activity.

Authors:  I J Zeitlin; S O Fagbemi; J R Parratt
Journal:  Cardiovasc Res       Date:  1989-02       Impact factor: 10.787

8.  Reperfusion-induced arrhythmias: mechanisms of protection by glucose and mannitol.

Authors:  M Bernier; D J Hearse
Journal:  Am J Physiol       Date:  1988-05
  8 in total
  12 in total

Review 1.  Role of bradykinin in preconditioning and protection of the ischaemic myocardium.

Authors:  G F Baxter; Z Ebrahim
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

2.  The local intracoronary administration of methylene blue prevents the pronounced antiarrhythmic effect of ischaemic preconditioning.

Authors:  A Vegh; J G Papp; L Szekeres; J Parratt
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

3.  Antiarrhythmic drug research.

Authors:  M J A Walker
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

4.  The effects of Z13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin.

Authors:  M A Rastegar; F Marchini; G Morazzoni; A Vegh; J G Papp; J R Parratt
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

5.  The antiarrhythmic effects of ischaemic preconditioning in anaesthetized dogs are prevented by atropine; role of changes in baroreceptor reflex sensitivity.

Authors:  László Babai; Julius Gy Papp; James R Parratt; Agnes Végh
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

6.  Delineation of a region in the B2 bradykinin receptor that is essential for high-affinity agonist binding.

Authors:  J Nardone; P G Hogan
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

7.  Prevention by an inhibitor of the L-arginine-nitric oxide pathway of the antiarrhythmic effects of bradykinin in anaesthetized dogs.

Authors:  A Vegh; J G Papp; L Szekeres; J R Parratt
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

8.  Preconditioning of the ischaemic myocardium; involvement of the L-arginine nitric oxide pathway.

Authors:  A Vegh; L Szekeres; J Parratt
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

9.  Suppression of reperfusion arrhythmia by ischemic preconditioning in the rat: is it mediated by the adenosine receptor, prostaglandin, or bradykinin receptor?

Authors:  T Miura; R Ishimoto; J Sakamoto; A Tsuchida; K Suzuki; T Ogawa; K Shimamoto; O Iimura
Journal:  Basic Res Cardiol       Date:  1995 May-Jun       Impact factor: 17.165

10.  A common mechanism in the protective effects of preconditioning, cardiac pacing and physical exercise against ischemia and reperfusion-induced arrhythmias.

Authors:  Agnes Végh; James R Parratt
Journal:  Exp Clin Cardiol       Date:  2005
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.